CD40 and neoplasm: Contrary to expectations, TGFβ blockade had no effect when combined with SBRT, and triple combination of SBRT, anti-CD40, and TGFβ blockade resulted in regression of the treated tumor, but complete loss of efficacy at the contralateral lesion (Figures 4D–F).